Antiviral activity | Patients infected with G4 HCV | ||
---|---|---|---|
T (N = 8) | TPR (N = 8) | PR (N = 8) | |
n (%) | n (%) | n (%) | |
Virologic responsea | |||
By end of TVR/Pbo treatment | 0 | 1 (12.5%) | 0 |
By EOT | 7 (87.5) | 6 (75.0) | 6 (75.0) |
Cumulative viral breakthrough | |||
By end of TVR/Pbo treatment | 5 (62.5) | 0 | 0 |
By EOT | 5 (62.5) | 2 (25.0) | 1 (12.5) |
Missing follow-up datac | 1 | 0 | 0 |
Relapseb | 1/7 (14.3) | 2/6 (33.3) | 1/6 (16.7) |
SVR24 | 5 (62.5) | 4 (50.0) | 5 (62.5) |